Analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.
Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.
Check Out Our Latest Stock Report on VNRX
VolitionRx Stock Performance
VolitionRx (NYSE:VNRX – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.34 million. Sell-side analysts expect that VolitionRx will post -0.31 EPS for the current fiscal year.
Insider Activity at VolitionRx
In other news, Director Guy Archibald Innes acquired 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the transaction, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.80% of the stock is currently owned by insiders.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Articles
- Five stocks we like better than VolitionRx
- How to Capture the Benefits of Dividend Increases
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- How to Invest in the Best Canadian Stocks
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- 3 Tickers Leading a Meme Stock Revival
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.